{"nctId":"NCT00391443","briefTitle":"BUILD 3: Bosentan Use in Interstitial Lung Disease","startDateStruct":{"date":"2007-02"},"conditions":["Idiopathic Pulmonary Fibrosis"],"count":616,"armGroups":[{"label":"Bosentan","type":"EXPERIMENTAL","interventionNames":["Drug: Bosentan"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Bosentan","otherNames":["Ro 47-0203","ACT-050088"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent\n* Male or female aged 18 years or older (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception.)\n* Proven diagnosis of IPF according to American Thoracic Society / European Respiratory Society (ATS-ERS) statement, of \\<3 years, with surgical lung biopsy (SLB)\n\nExclusion Criteria:\n\n* Interstitial lung disease due to conditions other than IPF.\n* Presence of extensive honeycombing (HC) on baseline high-resolution computed tomography (HRCT) scan.\n* Severe concomitant illness limiting life expectancy (\\<1 year).\n* Severe restrictive lung disease.\n* Obstructive lung disease.\n* Diffusing capacity of the lung for carbon monoxide \\<30% predicted.\n* Residual volume \\> or = 120% predicted.\n* Documented sustained improvement of patient's IPF condition up to 12 months prior to randomization with or without IPF-specific therapy.\n* Recent pulmonary or upper respiratory tract infection (up to 4 weeks prior to randomization).\n* Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements.\n* Chronic heart failure with New York Heart Association (NYHA) class III/IV or known left ventricular ejection fraction \\<25%.\n* Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) \\> 1.5 times the upper limit of the normal ranges.\n* Moderate to severe hepatic impairment.\n* Serum creatinine \\> or = 2.5 mg/dl or chronic dialysis.\n* Hemoglobin concentration \\<75% the lower limit of the normal ranges.\n* Systolic blood pressure \\<85 mmHg.\n* Pregnancy or breast-feeding.\n* Current drug or alcohol dependence.\n* Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):oral corticosteroids (\\>20 mg/day of prednisone or equivalent), immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine (prescribed for IPF).\n* Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease.\n* Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) up to 1 week prior to randomization.\n* Treatment with an endothelin receptor antagonist up to 3 months prior to randomization.\n* Participation in the BUILD 1 trial.\n* Treatment with another investigational drug up to 3 months prior to randomization or planned treatment.\n* Known hypersensitivity to bosentan or any of the excipients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Occurrence of Disease Worsening or Death up to End of Study.","description":"Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.","description":"Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"19.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":74,"n":209},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","IDIOPATHIC PULMONARY FIBROSIS","COUGH","DYSPNOEA","BRONCHITIS"]}}}